Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies ...

Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

The Danish drugmaker asked the agency to put semaglutide, the active ingredient in Wegovy and Ozempic, on a list of drugs ...

Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...